Covid Prompts Pharma To Move Away From Competition Driven Business Model

As deliberated in my just previous article in this blog, Covid has been a watershed in several areas of pharma business. One such key area is its competition driven strategic business model. It aims to deliver significant value for a … Continue reading

The issue of ‘Counterfeit Drugs’ in India: An “Ostrich Syndrome’

Ellen‘t Hoen, former Policy Advocacy Director of MSF’s Campaign for Access to Essential Medicines wrote in April 2009 as follows: “People often seem to confuse counterfeit, substandard and generic medicines – using the terms interchangeably. But they are very separate … Continue reading